New drug cocktail aims to stop deadly transplant complication
NCT ID NCT06315309
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times
Summary
This study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent a serious side effect called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial will enroll 29 adults aged 18-60 who have a matched donor. The goal is to see if this approach helps patients stay alive and free of severe GVHD or cancer relapse one year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.